Q-omics provides the consensus-scored CTSLP2 profile across patient tissues and cancer cell-line models. CTSLP2 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CTSLP2 is differentially expressed in 9, with the highest sampling consensus in THCA. Additionally, CTSLP2 RNA expression shows 11,764 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, THCA, and THYM as cancer lineages where CTSLP2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CTSLP2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CTSLP2 survival associations across molecular data types. CTSLP2 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CTSLP2 RNA expression–survival associations across cancer types. High CTSLP2 expression shows unfavorable associations in COAD, BLCA, UCEC, ACC and CHOL, but favorable associations in UVM. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CTSLP2 RNA expression.
This table summarizes CTSLP2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for CTSLP2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CTSLP2 shows lower tumor expression in THCA, KIRC, KICH, UCEC and KIRP and higher tumor expression in LIHC. The THCA box plot shows higher CTSLP2 RNA expression in normal versus tumor tissue (log2 FC = −1.203, t-test p < 0.001).
This table shows molecular features associated with CTSLP2 in patient tissues and cancer cell lines. In patient samples, CTSLP2 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
